Figure 3. Diagram demonstrating driver gene mutation status and clinicopathologic features in 198 adenocarcinomas from East Asian never-smoker females.

Most mutations were mutually exclusive with the rare exception of concurrent mutation of EGFR/PIK3CA (n = 3), EGFR/TP53 (n = 1), ALK/TP53 (n = 2), KRAS/PIK3CA (n = 1), and KRAS/ERBB2 (n = 1). Patients who received concurrent chemoradiation therapy and those who did not undergo lymph node dissection were excluded in the analysis of TNM stage.